Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hematologic Neoplasms 3 Primary Myelofibrosis 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Acute 2 Leukemia, Myeloid, Accelerated Phase 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Hodgkin Disease 2 Multiple Myeloma 1 Cytomegalovirus Infections 1

Interventions

Dexamethasone 242 Lenalidomide 147 daratumumab 125 Bortezomib 102 pomalidomide 88 Calcium Dobesilate 76 carfilzomib 75 Cyclophosphamide 71 Specimen Handling 42 isatuximab 41 Biopsy 40 belantamab mafodotin 37 fludarabine 36 Magnetic Resonance Spectroscopy 35 talquetamab 29 Melphalan 28 dexamethasone acetate 27 dexamethasone 21-phosphate 27 auricularum 26 iberdomide 25 ixazomib 22 fludarabine phosphate 22 selinexor 21 elotuzumab 21 Whole-Body Irradiation 14 X-Rays 13 tocilizumab 12 venetoclax 11 Mycophenolic Acid 10 trametinib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × letermovir × 1 year × Clear all

NCT06920251 2025-12-03

OPTIMUS-EL

Seoul National University Hospital

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡